Aptis Co., Ltd., a new drug development company that possesses the original technology of the ADC (antibody-drug conjugate) platform, announced on the 15th that it has recruited Dr. Young-Soo Oh as the head of the research institute (CTO) and vice president.
After graduating from Seoul National University’s Department of Chemistry, Young-Soo Oh received his Ph. Since then, he served as a research fellow at LG Life Sciences Research Fellow, Head of Research Division at Scripps Korea Antibody Research Institute, and Vice President of Bioneer New Drug Development. At LegoChemBio, he oversaw the research and development of new drugs including ADC as CTO and Executive Vice President.
As a project leader at LG Life Sciences, Shinim Oh, the head of the research institute, successfully researched and developed the oral anticoagulant, Thrombin Inhibitor, and the liver disease treatment, Caspase Inhibitor. Pfizer) and Gilead, a global bio company, have experience in exporting technology.
At LegoChemBio, he focused on ADC R&D and exported Her2 ADC technology to Fosun, one of the largest pharmaceutical companies in China, and signed a research license agreement with Takeda Oncology for joint R&D and ADC platform technology. He also has experience exporting
In the future, the new head of research institute and vice president Oh at Aptis will lead the research and development of ADC new drugs based on not only the experience leading the research and development of new drugs, but also the experience of exporting technology.
Sang-jeon Sang-jeon, CEO of Aptis, said, “With the joining of Young-soo Oh, the new head of the research center (CTO), with the joining of Aptis last year, Vice President Choi Won (CSO) from Severance Hospital, who has extensive clinical development experience in Merck (MSD) and LG Life Sciences, etc. It is expected that the R&D and clinical development of the ADC new drug pipeline will gain momentum at the same time.” In addition, after attracting investment at the beginning of this year, based on the success of attracting investment in Series B with a company value of 55 billion won, clinical and ADC development with global CRO and CDMO companies Cooperation will also begin soon.”
Aptis is a bio company that is developing new drugs with high Therapeutic Index for indications such as anticancer and immune diseases based on its own research and development and patented ADC platform technology. AbClick, the ADC platform technology developed by Aptis, has the site-specific properties of the linker’s antibody and does not require antibody mutation, so existing antibodies can be used as it is, which is also large in terms of immunogenicity and CMC. It has an advantage.
Aptis official said, “Aptis is also developing a new drug pipeline, and is currently conducting joint research on several ADC new drug pipelines through open innovation with several domestic and foreign antibody development companies and small molecule compound developers.” “In the ADC pipelines loaded with new antibodies and low-molecular substances using Aptis’ own ADC platform technology, not only Best in Class but also First in Class pipelines are included. It is expected to be of great help in signing an export contract.”
Hankyung.com News Room [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution